The H3antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers

Ahmed A. Othman, George Haig, Hana Florian, Charles Locke, Lev Gertsik, Sandeep Dutta
  • British Journal of Clinical Pharmacology, May 2014, Wiley
  • DOI: 10.1111/bcp.12281
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Dr Allison M Kitten

In partnership with: